Table 1.
Patient baseline, treatment, and prognostic characteristics of the entire cohort according to the ELN2022 risk stratification.
| n (%) | Cohort 130 (100) |
ELN2022 Favorable 20 (15.4) |
ELN2022 Intermediate 37 (28.5) |
ELN2022 Adverse 73 (56.1) |
p † |
|---|---|---|---|---|---|
| Age, years median (range) | 65 (18–94) | 50 (25–89) | 55 (18–89) | 69 (30–94) | <0.01 |
| Age ≥ 60 years | 82 (63.1) | 8 (40) | 16 (43.2) | 58 (79.5) | <0.01 |
| Sex, male n (%) | 71 (54.6) | 10 (50) | 13 (35.1) | 48 (65.8) | 0.009 |
| WBC × 109/L, median (range) | 10.4 (0.5–590) | 30 (1.2–158) | 22.4 (0.9–279) | 7.2 (0.5–590) | 0.02 |
| Clinical subtypes n (%) | |||||
| De-novo | 97 (74.6) | 17 (85.0) | 32 (86.5) | 48 (65.8) | 0.01 |
| s-AML | 21 (16.2) | 0 (-) | 2 (5.4) | 19 (26.0) | - |
| t-AML | 12 (9.2) | 3 (15) | 3 (8.1) | 6 (8.2) | - |
| NPM1 n(%) | 23 (17.7) | 10 (50) | 13 (35.1) | 0 (0) | <0.01 |
| FLT3-ITD n (%) | 23 (17.7) | 1 (5) | 16 (43.2) | 6 (8.2) | <0.01 |
| Received treatment n (%) | |||||
| Intensive chemotherapy (IC) | 87 (66.9) | 17 (85) | 29 (78.4) | 41 (56.2) | 0.01 |
| HMA-based/low intensity | 31 (23.9) | 3 (15) | 5 (13.5) | 23 (31.5) | - |
| Supportive care | 12 (9.2) | 0 (0) | 3 (8.1) | 9 (12.3) | - |
| HSCT * | 53 (61) | 6 (35) | 20 (69) | 27 (66) | 0.13 |
| Complete Remission (CR/CRi) * | 58 (66.6) | 16 (94.2) | 22 (75.8) | 20 (48.8) | <0.01 |
| Relapse rate * | 23 (26.4) | 4 (23.5) | 10 (34.5) | 9 (33.3) | 0.78 |
| Exitus rate | 80 (61.5) | 8 (40) | 19 (51.4) | 53 (72.6) | <0.01 |
ELN2022: European Leukemia Net 2022; WBC: white blood count; NPM1: nucleophosmine 1; FLT3-ITD: fms-like-tirosin kinase 3 internal tandem duplication; s-AML: secondary AML; t-AML: therapy-related AML; HMA: hypomethylating agents; HSCT: hematopoietic stem cell transplantation; * percentage calculated relative to the intensive treatment patient. † p value for three groups comparisons.